Lobeline sulfate

772.99

772.37600

205-151-8

4CJ480V2HP

DTXSID80158452

2933399090

164.06000

8.77580

1.085g/cm3

152-154 °C

485.6ºC at 760mmHg

247.5ºC

D20 -25° (c = 2)

III

6.1

2811

23/24/25

45-38-36/37/39-28A

OJ8490170

T

P264, P270, P301+P310, P321, P330, P405, P501

H301

|Danger|H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]|P264, P270, P301+P310, P321, P330, P405, and P501|Aggregated GHS information provided by 6 companies from 2 notifications to the ECHA C&L Inventory.

Agents that mimic neural transmission by stimulation of the nicotinic receptors on postganglionic autonomic neurons. Drugs that indirectly augment ganglionic transmission by increasing the release or slowing the breakdown of acetylcholine or by non-nicotinic effects on postganglionic neurons are not included here nor are the nonspecific cholinergic agonists. (See all compounds classified as Ganglionic Stimulants.)|Drugs used for their effects on the respiratory system. (See all compounds classified as Respiratory System Agents.)|Drugs that bind to and activate nicotinic cholinergic receptors (RECEPTORS, NICOTINIC). Nicotinic agonists act at postganglionic nicotinic receptors, at neuroeffector junctions in the peripheral nervous system, and at nicotinic receptors in the central nervous system. Agents that function as neuromuscular depolarizing blocking agents are included here because they activate nicotinic receptors, although they are used clinically to block nicotinic transmission. (See all compounds classified as Nicotinic Agonists.)

Lobeline